title: A PHASE III STUDY OF VELCADE (BORTEZOMIB) DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.

acronym: VD vesus VTD

lead_sponsor: Intergroupe Francophone du Myélome


title: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

source: euctr

lead_sponsor: Hospices Civils de Lyon

study_type: Interventional

status: Ongoing

lead_sponsor_type: academique

status_simplified: Ongoing


title: A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A as compared to the Dresden-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A.

acronym: FLU D-PAN H1N1-017

lead_sponsor: GlaxoSmithKline Biologicals

status: Completed

lead_sponsor_type: industriel

status_simplified: Completed


title: "MULTINATIONAL, PHASE III, RANDOMIZED STUDY TO EVALUATE TREATMENT CUSTOMIZED ACCORDING TO RAP 80 AND BRCA1 mRNA ASSESSMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (modification of the BREC study) "

acronym: BREC

lead_sponsor: ADDS (Advanced Drug Development Services)

status: Prematurely Ended

status_simplified: Unknown


title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma

lead_sponsor: CHU de Dijon


title: A Phase I Study of Ridaforolimus in Pediatric Patients with Advanced Solid Tumors

acronym: Oral MK8669 in Children/Adolescents with Solid Tumors (8-17 years)

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: An Open Label Multicenter Extension Study to Evaluate the Long-Term Efficacy and Safety of SBC 102 in Children with Lysosomal Acid Lipase Deficiency Who Previously Received Treatment with SBC-102

acronym: SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency

lead_sponsor: Synageva Biopharma Corp.


title: A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or 5x10E8 TU doses to placebo in HIV-1 clade B infected patients under highly active antiretroviral therapy

lead_sponsor: THERAVECTYS


title: IMPACTS Trial:  Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study:  Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients with Sickle Cell Disease and Vaso-occlusive Crisis)

lead_sponsor: Anthera Pharmaceuticals Incorporated


title: A randomized, double-blind, placebo-controlled, 4 period incomplete block cross-over, multi-center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 in patients with stable Chronic Obstructive Pulmonary Disease (COPD), compared to seven days treatment with tiotropium (18µg once daily, open label) as an active control.

lead_sponsor: Novartis Pharma Services AG


title:
An open-label, multi-center rollover protocol for patients
 who have participated in a Novartis-sponsored ribociclib
 (LEE011) study and are continuing to benefit from
 ribociclib as single agent or in combination with other
 investigational treatments

 Protocole multicentrique en ouvert évaluant la poursuite du traitement par ribociclib (LEE011) chez des patients ayant terminé leur participation à une étude promue par Novartis et qui continuent de bénéficier du ribociclib seul ou associé à d’autres traitements expérimentaux


title:
First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients

 Étude de première administration chez l’homme visant à évaluer la sécurité d’emploi, la tolérance, la pharmacocinétique, la pharmacodynamique et l’efficacité préliminaire du PPSGG (PN-1007) chez des patients atteints de neuropathie anti-MAG.

lead_sponsor: Polyneuron Pharmaceuticals AG


title: A phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive Organisms

lead_sponsor: Durata Therapeutic International B.V.


title:
A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory BAP1 deficientMalignant Mesothelioma

 Étude multicentrique de phase II de l’inhibiteur de l'EZH2 Tazemetostat chez des patients adultes atteints d'un mésothéliome malin en rechute ou réfractaire avec perte de fonction BAP1

lead_sponsor: Epizyme, Inc.


title:
Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or neither

 Essai clinique randomisé multicentrique du traitement endovasculaire de l’accident vasculaire cérébrale ischémique aigu. Effet du traitement médicamenteux péri-interventionnel : acide acétylsalicylique, héparine non fractionnée, les deux ou aucun

acronym:
MR CLEAN - MED

 MR CLEAN - MED

lead_sponsor: Erasmus MC University Medical Center


title: Sevrage de la ventilation mécanique guidé par le peptide natriurétique de type B.

acronym: BMW

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: ETUDE INTERNATIONALE DE PHASE II EVALUANT UNE ASSOCIATION CHOP-RITUXIMAB AVEC CONSOLIDATION PRECOCE PAR IBRITUMOMAB-TIUXETAN-Y90 CHEZ DES PATIENTS AGES DE 65 ANS A 80 ANS ATTEINTS D'UN LYMPHOME MALIN A GRANDES CELLULES CD20+ NON PRETRAITES

acronym: CHORIZO

lead_sponsor: CENTRE ANTOINE LACASSAGNE


title: OPTIMAL CONTROL OF LIVER METASTASES WITH INTRAVENOUS CETUXIMAB AND HEPATIC ARTERY INFUSION OF THREE-DRUG CHEMOTHERAPY IN PATIENTS WITH LIVER-ONLY METASTASES FROM COLORECTAL CANCER. A PHASE II TRIAL

lead_sponsor: ARTBC


title: Efficacy and Safety Assessment of Azyter® (T1225) in Peri-Operative Antibio-Prophylaxis (ocular surface decontamination) for Cataract Surgery

lead_sponsor: Laboratoires Théa


title: Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma

lead_sponsor: Amgen Inc


title: A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients with Stages 3 to 5 Chronic Kidney Disease Undergoing MRI with the Injection of ProHance

acronym: Evaluation of the Incidence of NSF Following ProHance Injection

lead_sponsor: Bracco Imaging S.p.A.


title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002

lead_sponsor: Edimer Pharmaceuticals, Inc.


title:
D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study

 INTERET DE LA CHIMIOHYPERTHERMIE INTRAPERITONEALE (CHIP) ADJUVANTE A L’OXALIPLATINE DANS LE TRAITEMENT CURATIF DES CANCERS GASTRIQUES AVANCES. ETUDE NATIONALE, RANDOMISEE ET MULTICENTRIQUE DE PHASE III.

acronym:
GASTRICHIP

 GASTRICHIP

lead_sponsor: Hospices Civils de Lyon


title: FIVHeMA: Intraventricular fibrinolysis versus external ventricular drainage alone in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.

acronym: FIVHEMA

lead_sponsor: CHU CAEN


title: SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy

lead_sponsor: Asahi Kasei Pharma America Corporation


title: Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA

lead_sponsor: Abeona Therapeutics Inc


title: A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis


title: An Open-Label Extension Study Evaluating the Long-Term Safety of ICA 17043 with or without Hydroxyurea Therapy in Subjects with Sickle Cell Disease

lead_sponsor: Icagen Inc.


title: A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multiple oral doses of AFQ056

lead_sponsor: Novartis Pharma Services AG


title: Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose  péritonéale d'origine colorectale associée à une chimiothérapie systémique.

acronym: CHIP

lead_sponsor: FNCLCC


title: VALIDATION OF DYSKINESIA RATING SCALES

lead_sponsor: Michael J. Fox Foundation for Parkinson’s Research


title:
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia

 Une étude ouverte multicentrique avec titrage de la posologie du chlorhydrate de nevanimibe dans le traitement de l’hyperplasie congénitale des surrénales classique

lead_sponsor: Millendo Therapeutics, Inc.


title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)

lead_sponsor: Fulcrum Therapeutics, Inc.


title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)

lead_sponsor: HANLIM PHARM CO., LTD


title: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer

lead_sponsor: ARIAD Pharmaceuticals, Inc.


title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previously untreated adults with B and C Binet stage B-chronic lymphoid leukemia (B-CLL).

acronym: CLL 2007 FMP

lead_sponsor: GOELAMS


title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB)

lead_sponsor: Genentech, Inc.


title:
SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation.
 An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients with Atrial Fibrillation undergoing Electric Cardioversion Following Transesophageal Echocardiography.

acronym: SAFE-AF

lead_sponsor: GlaxoSmithKline R & D


title: A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia

lead_sponsor: Clavis Pharma ASA


title:
A phase I/II multicenter, open-label study of CLR457 administered orally
 in adult patients with advanced solid malignancies


title: A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias

lead_sponsor: Osmotica Pharmaceutical Corp.


title:
IFM 2014-02 study: A randomized phase III study of Bortezomib-Melphalan 200 conditioning regimen versus Melphalan 200 for frontline transplant eligible patients with multiple myeloma

 Etude IFM 2014-02:
 Intérêt d’un conditionnement par bortezomib-melphalan 200 vs melphalan 200 suivi d’une autogreffe de cellules souches chez les patients de moins de 66 ans atteints de myélome multiple en première ligne: une étude randomisée de phase III de l’IFM

acronym: Etude IFM 2014-02

lead_sponsor: CHU Toulouse


title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in Patients with Previously Treated, incurable Ewing Sarcoma

lead_sponsor: Sarcoma Alliance for Research Through Collaboration (SARC)


title: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer

acronym: TENACITY

lead_sponsor: Ayala Pharmaceuticals, Inc.


title:
A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU/dL and Pre-existing Antibodies Against AAV5

 Etude de Phase 1/2 destinée à évaluer la sécurité, tolérance, et l’efficacité du BMN 270, un vecteur viral adéno-associé pour le transfert de gène du facteur VIII Humain chez des patients atteints d’hémophilie A ayant des taux de base de FVIII ≤ 1 IU/dL et des anticorps préexistants contre AAV5

lead_sponsor: BioMarin Pharmaceutical Inc.


title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therapy) administered in combination with anti-VEGF therapy

lead_sponsor: OPHTHOTECH CORPORATION


title: A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson’s disease

lead_sponsor: Integrative Research Laboratories Sweden AB (IRLAB)


title:
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

 Étude de phase III, randomisée, en ouvert, contrôlée, multicentrique, évaluant l’efficacité et la tolérance du Savolitinib versus Sunitinib chez des patients atteints d’un carcinome papillaire rénal non opérable localement avancé ou métastatique avec mutation MET

lead_sponsor: AstraZeneca


title:
Phase I/II feasibility study of Brentuximab Vedotin in refractory / relapsed Hodgkin lymphoma patients who are treated by chemotherapy (ICE) in second line and eligible for autologous transplantation

 Etude de faisabilité de phase I/II du Brentuximab vedotin chez des patients atteints d'un Lymphome de Hodgkin en rechute ou réfractaire, traités par chimiothérapie (ICE) en seconde ligne et éligibles à l'autogreffe.

acronym: BV-ICE

lead_sponsor: LYSARC


title:
A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions

 Etude de phase II évaluant le nivolumab seul ou en association à la vinblastine chez des patients atteints d’un lymphome de Hodgkin classique, âgés de 61 ans et plus et présentant des co-morbidités


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis

acronym: Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS

lead_sponsor: Biogen Idec Research Limited


title: A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders.

lead_sponsor: Neurochlore


title:
A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome

 Étude de phase II multicentrique non-randomisée évaluant le traitement par un inhibiteur d’IDH1 (AG-120) chez des patients présentant un syndrome myélodysplasique avec mutation IDH1

lead_sponsor: Groupe Francophone des Myelodysplasies


title: Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have received radical surgery. A European Association of Urology Research Foundation Phase II Clinical Trial

acronym: Adjuvant Pemigatinib in surgically treated high-risk UC

lead_sponsor: EAU Research Foundation


title:
Comparison of the analgesic effect of a new paracetamol formulation (paracetamol UNIFLASH) for buccal use and two different doses of an oral paracetamol form controlled versus placebo in patients suffering from moderate pain due to a tooth extraction.

 Comparaison de l’effet analgésique d’une nouvelle formulation de paracétamol (paracétamol UNIFLASH) à usage buccal et de deux doses différentes d’une forme orale de paracétamol, contrôlée versus placebo, chez des patients souffrant de douleurs modérées dues à une extraction dentaire

acronym: PARAMOUTH

lead_sponsor: UNITHER Pharmaceuticals


title: A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

lead_sponsor: Incyte Corporation


title: Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy

lead_sponsor: AXCAN PHARMA SAS


title: A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

lead_sponsor: SynCore Biotechnology Co., Ltd.


title:
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis treated by R-CHOP

 Etude de phase Ib-II du tazemetostat (EPZ-6438) chez des patients
 atteints de lymphome diffus à grandes cellules B (DLBCL) de
 risque élevé traités par R-CHOP


title: A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II.

acronym: ACCELA

lead_sponsor: sanofi-aventis recherche & développement


title: A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chronic hepatitis B.

acronym: NEPTUNE

lead_sponsor: F.Hoffmann-La Roche Ltd


title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.

lead_sponsor: Galderma Research and Development SNC


title: A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis.

acronym: Transition to RNF

lead_sponsor: Merck Serono International SA


title: Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Twelve-week treatment plus double-blind extension for 12 weeks.

lead_sponsor: Institut de Recherches Internationales Servier


title: A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator-Associated Pneumonia

lead_sponsor: Janssen Cilag International NV


title: A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma

acronym: IGF-1R protocol

lead_sponsor: Cliniques Universitaires Saint Luc-Centre du Cancer


title: A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colorectal liver metastases

lead_sponsor: Micromet AG


title: An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of  a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older

lead_sponsor: Sanofi Pasteur MSD S.N.C.


title: A phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Infants Aged 1 to 11 months, Inclusive

lead_sponsor: AstraZeneca AB


title: Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.

lead_sponsor: Orfagen


title: A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older


title: Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44

acronym: Principle -TIMI 44

lead_sponsor: Eli Lilly and Company


title: An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression.

lead_sponsor: Boehringer Ingelheim France


title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, 100 and 200 mg) vs Placebo in Patients with Overactive Bladder.

lead_sponsor: Helsinn Healthcare SA


title: A MULTICENTER, RANDOMIZED, INTRA-INDIVIDUAL, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD2027 OINTMENT 9µG/G APPLIED TWICE DAILY OVER 4 WEEKS IN THE TREATMENT OF TARGET LESIONS IN ADULTS SUBJECTS WITH ATOPIC DERMATITIS.

lead_sponsor: Galderma R&D SNC


title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regimen

acronym: DORAL

lead_sponsor: Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida  (CREPATS)


title: Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 15-Aug-06)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A multi-center, double-blind, randomized, placebo-controlled, titration study to investigate the safety, the tolerability and the pharmacodynamic profiles of different doses of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin.

lead_sponsor: F. Hoffmann-La Roche Ltd


title: Calcipotriol Plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas

lead_sponsor: LEO Pharma A/S


title: A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours, Lymphomas and Endometrial Carcinoma

lead_sponsor: Astrazeneca AB


title: A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

lead_sponsor: Pharma Mar, S.A.


title: A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1 Chronic Hepatitis C

lead_sponsor: Idenix Pharmaceuticals, Inc.


title: Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.

lead_sponsor: IBSA, Institut Biochimique SA


title: Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) delivered by the Respimat® inhaler in patients with asthma

acronym: BI 1744 CL in Asthma


title: An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15μg) versus an Inactivated adjuvanted Influenza Vaccine administered by Intramuscular Route (Addigrip® 15µg) in subjects 65 years of age or older

lead_sponsor: Sanofi Pasteur MSD


title: A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders.


title: A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer

lead_sponsor: Amgen Inc.


title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis

lead_sponsor: Amgen Inc


title: Long-term, open-label, multicenter extension study of bosentan in patients with pulmonary hypertension associated with sickle cell disease completing a double-blind ASSET study (AC-052-368 or AC-052-369)

lead_sponsor: Actelion Pharmaceuticals Ltd.


title: Randomised, double-blind, placebo-controlled, Phase II study to assess the safety and efficacy of different doses of intravenous APD405 (buspirone for IV injection) for the prevention of post-operative nausea and vomiting

lead_sponsor: Acacia Pharma Ltd.


title: A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with severe COVID-19

acronym: ESsCOVID

lead_sponsor: Biotest AG


title: Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatique

lead_sponsor: UCL Saint Luc 1200 Bruxelles


title: Standardized sTudy with Almotriptan in eaRly Treatment of migraine, START. An international, open-label, single arm, effectiveness and safety study of Almotriptan in primary care seeting.

acronym: START

lead_sponsor: Laboratorios Almirall SA


title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone.

lead_sponsor: F.Hoffmann-La Roche Ltd


title: A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations.

acronym: MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia (CIN1).

lead_sponsor: Photocure ASA


title: Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

acronym: AURA

lead_sponsor: Insitut Jules Bordet


title: Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial

acronym: neo-checkray

lead_sponsor: Institut Jules Bordet


title: A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

acronym: Phase 3 Study of Belantamab Mafodotin Plus VRd vs. VRd in Transplant Ineligible Newly Diagnosed MM

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular toxicity in cancer patients treated with SYD985.

lead_sponsor: Byondis B.V.


title: Diagnostic value of 18F-choline PET/CT for the detection of systemic prostate cancer disease.

lead_sponsor: CIS bio international, member of IBA group


title: Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma.


title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF  I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)

lead_sponsor: LFB BIOTECHNOLOGIES


title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

acronym: SYNERGY trial


title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma

lead_sponsor: Nerviano Medical Sciences S.r.l.


title: An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation in adult patients.

lead_sponsor: EUSA Pharma


title: An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with  Relapsed Diffuse Large B-Cell Lymphoma

lead_sponsor: Eli Lilly and Company limited


title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis.

acronym: BATT (Biclutamide anatrozole treatment for testotoxicosis)

lead_sponsor: AstraZeneca AB


title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence

lead_sponsor: Allergan Ltd


title:
A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

 Étude multicentrique ouverte, avec bras de contrôle randomisé, portant sur l'efficacité, l'innocuité et la pharmacocinétique de la bérubicine administrée par perfusion intraveineuse à des patients adultes atteints de glioblastome multiforme récidivant (grade IV de l'OMS) après échec du traitement standard de première intention.

lead_sponsor: CNS Pharmaceuticals, Inc.


title: An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancer

acronym: NERABRAIN


title: Efficacy of Oscillococcinum® in the treatment of Influenza-like-illness symptoms: a national, multicentre, randomized, controlled trial

acronym: GOSCI

lead_sponsor: BOIRON


title:
Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria

 Etude multi-centrique, en ouvert, évaluant la sécurité d’emploi, la tolérabilité, l’efficacité, l’observance et l’acceptabilité de traitements alcalinisants à long terme chez des patients présentant une cystinurie.

lead_sponsor: Advicenne


title: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome

lead_sponsor: Emalex Biosciences, Inc.


title:
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

 Étude de phase 2 à double cohorte, en ouvert portant sur le brentuximab védotine et le CHP (A+CHP) dans le traitement de première ligne de patients atteints de lymphome à cellules T périphérique (LCTP) avec moins de 10 % d’expression de CD30

lead_sponsor: Seattle Genetics, Inc.


title:
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone

 DENOEUROSARC-007 - Etude de phase 2 multicentrique, en ouvert du denosumab chez des patients présentant des tumeurs osseuses riches en cellules géantes

acronym:
DENOEUROSARC-007

 DENOEUROSARC-007

lead_sponsor: Leiden University Medical Center


title:
A Phase 1/2, Open-Label, Multicenter Study of INCB000928
 Administered as a Monotherapy in Participants With Anemia Due to
 Myelodysplastic Syndromes or Multiple Myeloma

lead_sponsor: Incyte Corporation


title:
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer

 Étude de phase 2 à deux cohortes portant sur FL-101 en traitement néoadjuvant chez des patients atteints d’un cancer bronchique non à petites cellules opérable

acronym: Phase 2 Study of FL-101 in NSCLC

lead_sponsor: Flame Biosciences


title: A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemotherapy and Anti-PD-[L]1 Immunotherapy

acronym: CheckMate 79X: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 79X

lead_sponsor: Bristol-Myers Squibb International Corporation


title: "Etude en simple aveugle évaluant l'efficacité et la tolérance du BF 2.649 dans le trouble de l'attention/hyperactivité de l'adulte"

lead_sponsor: BIOPROJET


title:
Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemia

 Évaluation de la l'efficacité, du délai d'action, et de la tolérance de Tot'héma® chez l'adulte présentant une anémie modérée ferriprive

acronym: FAST

lead_sponsor: Laboratoire Innotech Internationnal


title: A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

lead_sponsor: CuraGen Corporation


title: Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine (T4) soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients.

lead_sponsor: IBSA, Institut Biochimique SA


title:
A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma
 Revised Protocol Number 01, incorporating Amendment 02 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06


title: A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY

lead_sponsor: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK


title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of  Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer

lead_sponsor: Bristol Myers Squibb International Corporation


title: A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy

lead_sponsor: Cliniques Universitaires St Luc


title: Phase Ib/II, Multicenter, Open-Label, Randomized, Clinical Study with Dose Optimization of Two Different Schedules of Elisidepsin Trifluoroacetate (Irvalec®) as a Single Agent in Patients with Unresectable, Locally Advanced or Metastatic Esophageal, Esophagogastric Junction or Gastric Cancer After Failure of One but not More than Two Prior Lines of Systemic Therapy

acronym: IMAGE

lead_sponsor: Pharma Mar, S.A. Sociedad Unipersonal


title:
A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients
 Revised Protocol Number 02, incorporating amendments 03 and 04


title: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment

lead_sponsor: Allergan


title: EFFICACY AND SAFETY STUDY OF WILFACTIN ADMINISTERED BY CONTINUOUS INFUSION IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING MAJOR SURGICAL PROCEDURES

lead_sponsor: LFB BIOTECHNOLOGIES


title: A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma

lead_sponsor: Exelixis, Inc.


title: A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc.


title: A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing  SCH 420814 5 mg BID

lead_sponsor: Schering Plough Research Institute


title: Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5083945, a Glycoengineered Antibody against EGFR, in patients with metastatic and/or locally advanced malignant EGFR+ Solid Tumors

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease followed by a 38-Week open-label extension phase


title: A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINISTERED ORALLY TO SUBJECTS WITH ADVANCED SOLID TUMORS, NON-HODGKIN’S LYMPHOMA OR MULTIPLE MYELOMA

lead_sponsor: Celgene Corporation


title:
Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients  with advanced or metastatic solid tumors
 International, multicenter, open label study

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis

acronym: VOCAL

lead_sponsor: Aurinia Pharmaceuticals Inc.


title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA

acronym: VALYM

lead_sponsor: LYSARC


title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)

lead_sponsor: INSERM


title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to
 Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

lead_sponsor: Incyte Corporation

status: Not Authorised


title:
A GLP-1 receptor PET imaging substudy within the VER-AT1D trial investigating the effects on beta cell mass.

 Etude de l’imagerie TEP du récepteur GLP-1,  compagnon de l’étude Ver-A-T1D évaluant les effets d’une thérapie sur la masse des cellules bêta pancréatiques.

acronym:
PET imaging of beta cells in Type 1 diabetes, effect of verapamil (Image-Ver-A-T1D)

 Imagerie TEP des cellules bêta dans le diabête de Type 1 , effet du vérapamil (Image-Ver-A-T1D)

lead_sponsor: Radboud University Medical Center


title:
A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism
 Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

acronym: PARTUM

lead_sponsor: CHU SAINT-ETIENNE


title:
A Phase II, randomized, double-blind, parallel group dose finding study of single oral doses of moxidectin in adults with scabies

 Étude de phase II, randomisée, en double aveugle, en groupes parallèles, destinée à l'établissement de la posologie de la moxidectine en prise unique par voie orale chez des adultes atteints de la gale

lead_sponsor: Medicines Development Limited (trading as Medicines Development for Global Health)


title: A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours

acronym: FOREST

lead_sponsor: University of Birmingham


title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children

lead_sponsor: Advicenne


title: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

lead_sponsor: Seagen Inc.


title:
A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma.

 Etude de phase Ib/II de l’Obinutuzumab (GA101) combiné au lenalidomide pour le traitement du lymphome folliculaire et du lymphome agressif à cellules B (DLBCL et MCL) réfractaire ou en rechute.

acronym: GALEN

lead_sponsor: GELARC


title: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE

acronym: PROPEL OLE

lead_sponsor: QED Therapeutics, Inc.


title: A MULTI-CENTRE, SINGLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS OF PITOLISANT (BF2.649) IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY

acronym: PITOLISANT PHARMACOKINETICS SINGLE DOSE TRIAL IN CHILDREN  FROM 6 TO LESS THAN 18 YEARS OLD

lead_sponsor: Bioprojet Pharma


title: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer

lead_sponsor: SOLTI


title: An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and progressive metastatic cutaneous melanoma

acronym: MAGE3-AS15-MEL-002 (MET-chemo)

lead_sponsor: GlaxoSmithKline Biologicals


title: Etude de phase III randomisée, ouverte, multicentrique comparant chez des sujets âgés de plus de 70 ans atteints de cancer bronchique non à petites cellules de stade IV ou IIIb (T4 plèvre ou péricarde) une stratégie « classique » d’attribution d’un traitement par bithérapie à base de carboplatine ou une monothérapie par Docetaxel seul basée sur le PS et l’âge à une stratégie « optimisée » utilisant les mêmes drogues attribuées selon une échelle gériatrique simplifiée de dépistage plus ou moins complétée d’une évaluation gériatrique approfondie

acronym: esogia

lead_sponsor: CHU de Rennes


title: A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

lead_sponsor: Millennium Pharmaceuticals, Inc


title:
A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

 Étude multinationale dans le but de recueillir des échantillons de sang pour l’exploration de paramètres génétiques et de biomarqueurs potentiels liés à une augmentation du risque de lésion hépatique chez les patients adultes ayant précédemment participé aux essais cliniques du tolvaptan dans le traitement de la polykystose rénale autosomique dominante (PKRAD)

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.


title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy

lead_sponsor: Biotec Pharmacon ASA


title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs

acronym: HDL functionality

lead_sponsor: F. HOFFMANN-LA ROCHE LTD


title: A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the treatment of Post-Operative Ileus (POI)

lead_sponsor: Progenics Pharmaceuticals, Inc.


title: A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial.

lead_sponsor: TRB CHEMEDICA INTERNATIONAL SA


title: A randomised, double-blind, placebo-controlled study to assess the safety and activity of pentosan polysulfate sodium on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain in patients with sickle cell disease

acronym: A Study of PPS in Sickle Cell Disease

lead_sponsor: TRF Pharma, Inc.


title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Two-arm Safety and Efficacy Study of SYN118 as Adjunctive Therapy in Subjects with Parkinson‟s Disease

lead_sponsor: Synosia Therapeutics AG


title: Evaluation de l’efficacité de l’association ibuprofène et codéine versus l’ibuprofène seul dans le traitement de la poussée douloureuse de la gonarthrose. Etude en double aveugle, randomisée contrôlée de 2 groupes parallèles de patients traités pendant 7 jours.

acronym: EVACOD

lead_sponsor: Laboratoires ELERTE


title:
Genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

 Etude d’allocation génétique de la prophylaxie antifongique chez les patients traités pour une leucémie aiguë myéloïde

acronym:
PTX3-AML

 PTX3-AML

lead_sponsor: Centre Hospitalier Universitaire Vaudois


title: A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TOEVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BFKB8488A COMPAREDWITH PLACEBO IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS.

lead_sponsor: Genentech Inc


title: Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) with a documented upper respiratory tract infection (URTI) with respiratory syncytial virus (RSV)

lead_sponsor: ReViral Ltd.


title:
A Randomized Study  of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery

 Etude randomisée comparant Paclitaxel-Carboplatine suivi d’une maintenance par Niraparib avec Paclitaxel-Carboplatine-Bevacizumab suivi d’une maintenance par Niraparib + Bevacizumab chez des patientes atteintes d’un cancer de l’ovaire avancé après une chirurgie de cytoréduction initiale complète

lead_sponsor: ARCAGY-GINECO


title: A randomized, double-blind, placebo-controlled, cross-over trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by functional magnetic resonance imaging (FMRI) of the brain

lead_sponsor: Aarhus University


title: Cure COVID: A prospective, controlled, randomized study to compare the efficacy of GNS561 versus standard of care in patients with SARS-CoV-2 (COVID-19) infection.

lead_sponsor: Genoscience Pharma


title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma

lead_sponsor: Centre Oscar Lambret


title: Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial

lead_sponsor: Astion Pharma A/S


title: Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)

lead_sponsor: NeuroVia, Inc.


title: Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)

lead_sponsor: Intellia Therapeutics, Inc.


title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease

lead_sponsor: Biogen Idec Research Limited


title: A Multicenter, Three- arm, Double- blind, Double dummy, Parallel-group, placebo controlled Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily in comparison with conventional release formulation of Betahistine IR 24 mg, twice daily in treatment of adult patients with Menière's disease.

acronym: BERTIGO

lead_sponsor: INTAS PHARMACEUTICALS LIMITED


title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS)

acronym: CARDINALS

lead_sponsor: PTC Therapeutics, Inc.


title: An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed By an Open-Label Long-Term Extension

lead_sponsor: Pharming Technologies B.V.


title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

lead_sponsor: Harpoon Therapeutics, Inc.


title:
A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) patients.

 Étude de Phase III du JR-141 chez des patients atteints d’une mucopolysaccharidose de type 2 (Maladie de Hunter).

lead_sponsor: JCR Pharmaceuticals Co., Ltd.


title: A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HSCT)

lead_sponsor: Priothera S.A.S.


title: A randomized, open label multicenter trial to investigate the efficacy of a treat-to-target treatment strategy with secukinumab (AIN457) as a first-line biologic compared to a standard-of-care treatment over 36 weeks in patients with active axial spondyloarthritis (axSpA) - AScalate

acronym: AScalate

lead_sponsor: Novartis Pharma GmbH


title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age

lead_sponsor: Biohaven Pharmaceuticals Holding Company Limited


title:
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

 Essai clinique en ouvert, à bras unique de phase II des lymphocytes T ADP-A2M4 SPEARTM chez des patients atteints de sarcome synovial avancé ou de liposarcome myxoïde/à cellules rondes (LSMCR)

acronym: SPEARHEAD 1 STUDY

lead_sponsor: Adaptimmune LLC


title: Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care

acronym: VASE

lead_sponsor: Cliniques Universitaires Saint-Luc (CUSL)


title: In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX)

lead_sponsor: Wyeth Pharmaceuticals


title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitis

lead_sponsor: Stallergenes S.A.


title: An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients

lead_sponsor: MediGene AG


title: EFFICACY STUDY OF THE ANTIHISTAMINE V0114 CP 2.5MG TABLET IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS.  A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibrate 160mg/Pravastatin 40mg combination versus Simvastatin 20mg in patients without Cardiovascular disease (CVD) (group 1) and of Fenofibrate 160mg/Pravastatin 40mg combination+Ezetimibe 10mg versus Simvastatin 20mg+Ezetimibe 10mg in patients with CVD (group 2), followed by a 12-week safety phase of  Fenofibrate 160mg/Pravastatin 40mg combination in group 1 and of Fenofibrate 160mg/Pravastatin 40 mg combination+Ezetimibe 10mg in group 2.

acronym: PREFED "PRavastatin, Ezetimibe and FEnofibrate in Diabetic patients"

lead_sponsor: Laboratoires SMB S.A.


title: A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

acronym: FEDEGYN 01/0902  - PORTEC 3

lead_sponsor: Leiden University Medical Centre


title: A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

lead_sponsor: Novartis Pharma Service AG


title: A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell Lung Cancer who Have Failed One Prior Platinum-based Chemotherapy Regimen.

lead_sponsor: AstraZeneca AB


title: A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)

lead_sponsor: BTG International Ltd


title: Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.

lead_sponsor: ASSOCIAZIONE QOL-ONE


title: A phase II study of CP-4126 in patients with advanced pancreatic cancer

lead_sponsor: Clavis Pharma ASA


title: Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anemia

lead_sponsor: Schering-Plough Research Institution, A Division of Schering Corporation


title: An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

acronym: Not applicable.

lead_sponsor: Novartis Pharma Services AG


title: Non inferiority study of a malathion 0.5% lotion versus reference therapy in the treatment of head lice: multicentre, randomised, investigator masked, parallel group.

lead_sponsor: Pierre Fabre Dermo-Cosmétique


title:
A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency

 Etude de Phase II, multicentrique, randomisée, en ouvert, de doses répétées, de comparaison de doses, visant à évaluer la tolérance, l’efficacité et la pharmacocinétique de la sphingomyelinase acide humaine recombinante chez des patients avec un déficit en sphingomyelinase acide

lead_sponsor: Genzyme Corporation


title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants

lead_sponsor: Fresenius Kabi Deutschland GmbH


title: An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients

acronym: Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

lead_sponsor: Alcon Research Ltd


title: A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in patients with Prader-Willi Syndrome

lead_sponsor: Alize Pharma


title:
A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors

 Etude Clinique de phase I/II, multicentrique et en ouvert, évaluant l'administration intratumorale/lésionnelle de RGT100 chez des patients atteints de tumeurs avancées ou récidivantes.

acronym: A Phase I/II trial of intralesional administration of RGT100

lead_sponsor: Rigontec GmbH


title: A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutations

lead_sponsor: Array BioPharma Inc.


title:
AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS)

 ÉTUDE EXPLORATOIRE OUVERTE ÉVALUANT L’UCB5857 CHEZ DES PATIENTS PRÉSENTANT UN SYNDROME DE PHOSPHO-INOSITIDE-3-KINASE (PI3K) DELTA ACTIVÉE (SYNDROME APDS)

lead_sponsor: UCB Celltech, UK Registered Branch of UCB Pharma SA


title: Colchicine Cardiovascular Outcomes Trial (COLCOT)

acronym: COLCOT

lead_sponsor: Montreal Heart Institute


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1)

lead_sponsor: Revance Therapeutics Inc


title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER

lead_sponsor: Vanda Pharmaceuitcals Inc.


title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) – (KEYNOTE-086)

acronym: A Phase II Study of Pembrolizumab in Subjects with Triple-Negative Breast Cancer

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.

lead_sponsor: Theratechnologies Inc.


title: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)

acronym: CYSIF

lead_sponsor: GETAID


title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age

lead_sponsor: Sanofi Pasteur MSD SNC


title: A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because of virologic failure/lack of response.

lead_sponsor: Avexa Limited


title: A Phase III, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0826/Ertapenem and Meropenem in Patients with Complicated Urinary Tract Infections

lead_sponsor: Merck & Co., Inc.


title: A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Medial Thickness (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

acronym: Carotid IMT Study

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: An Open-Label Evaluation of Safety of the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)] for Management of Acute Post- Operative Pain in Pediatric Patients

lead_sponsor: Janssen Cilag International N.V.,


title: Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab

acronym: EUSpA

lead_sponsor: Schering-Plough France


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients.


title: ASSESSMENT OF GLOBAL AND REGIONAL LEFT VENTRICULAR FUNCTION AT REST AND DURING DOBUTAMINE STRESS WITH SONOVUE®-ENHANCED REALTIME 3D-ECHOCARDIOGRAPHY

lead_sponsor: Bracco ALTANA Pharma GmbH


title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin

lead_sponsor: Laboratoires MSD-Chibret


title: A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.


title: A randomised, double-blind, double-dummy, active-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 90.9 181.8 and 363.6 μg b.i.d. administered via Respimat® inhaler and fluticasone propionate HFA MDI 440 μg b.i.d. in patients with asthma inadequately controlled on medium dose ICS therapy

lead_sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG


title:
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

 Essai de phase II, en ouvert, de pazopanib en monothérapie chez des patients porteurs de tumeurs fibreuses solitaires (SFT) et chondrosarcomes myxoïdes extra squelettiques (EMC), non résécables ou métastatiques.

acronym:
GEIS-32

 GEIS-32

lead_sponsor: Grupo Español de Investigación en Sarcomas


title: A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial hypertension

acronym: FUTURE 6

lead_sponsor: Actelion pharmaceuticals Ltd


title: L'Erythropoïetine dans les traumatismes crâniens (EPO-TBI)

acronym: EPO-TBI

lead_sponsor: Monash University


title: A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence

lead_sponsor: Laboratoires Merck Sharp & Dhome-Chibret


title: A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer

lead_sponsor: Novartis Pharma Services AG


title: A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

lead_sponsor: NeuroDerm Ltd.


title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension

lead_sponsor: Conatus Pharmaceuticals Inc.


title:
A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART.

 Essai randomisé évaluant une thérapie antirétrovirale basée sur le dolutegravir (DTG) en comparaison avec une thérapie antirétrovirale standard chez les enfants infectés par le VIH-1 commençant une première ligne ou  changeant pour une seconde ligne de traitement.

acronym: ODYSSEY (Once daily DTG-based ART in young people vs standard therapy)

lead_sponsor: Fondazione PENTA ONLUS


title: A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1β Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA)


title: A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis


title: An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.

lead_sponsor: Neurochem Inc


title: Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012

lead_sponsor: NV Organon


title: A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired renal function


title: A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the sequential add-on treatment strategies in patients with essential hypertension.

acronym: ACCELERATE: Aliskiren and the Calcium Channel BlockEr amLodipine combination as an initial trEatment


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

lead_sponsor: Merck & Co., Inc.


title: A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on Bone Micro-architecture in Postmenopausal Women Treated with Vitamin D


title: A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia

lead_sponsor: Protherics Medicines Development Ltd


title: A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis

lead_sponsor: AbbVie Deutschland GmbH & Co. KG


title: "A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritis"


title: A phase II, randomized, partially double blind, controlled study to evaluate the immunogenicity, safety, and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis (RA) who have relapsed despite use of an anti-TNFα biological drug, due to anti-drug antibodies

lead_sponsor: Neovacs SA


title:
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)

 Étude de recherche de dose randomisée, en double aveugle, contrôlée par placebo visant à évaluer la sécurité et l’efficacité du CCX140-B chez des sujets atteints de hyalinose segmentaire et focale (HSF)

lead_sponsor: ChemoCentryx, Inc.


title: A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a stable dose of a second generation antipsychotic.

acronym: Glycine uptake Inhibitor Add-on in Negative symptoms Trial (GIANT).


title: OFA110867 : Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapy


title: An open-label, non-controlled multicentre trial to evaluate the insertion characteristics of the radiopaque etonogestrel implant using a next generation applicator


title: Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy

lead_sponsor: PIERRE FABRE MEDICAMENT


title: Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary

lead_sponsor: Kitasato institute clinical trial coordinating center


title: Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders :  randomised, placebo-controlled, dose effect, double blind, parallel group study

lead_sponsor: PIERRE FABRE MEDICAMENT-IRPF-IDPF


title:
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR)

 Essai randomisé de phase II comparant l'Imatinib versus Imatinib + hydroxychloroquine chez les patients atteints d’une leucémie myéloïde chronique en phase chronique, en réponse cytogénétique majeure, mais avec une maladie résiduelle détectable par PCR (polymerase chain reaction)

acronym: CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cells

lead_sponsor: NHS Greater Glasgow and Clyde


title: A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease

lead_sponsor: ApoPharma Inc.


title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) versus placebo in women with Mixed Urinary Incontinence

lead_sponsor: IXALTIS


title:
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer.

 Étude de phase II, randomisée, en double aveugle, contrôlée par placebo, portant sur le traitement néoadjuvant par carboplatine et paclitaxel, avec ou sans Debio 1143, chez des patientes atteintes d'un cancer épithélial nouvellement diagnostiqué et avancé de l'ovaire

lead_sponsor: Debiopharm International SA


title:
A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

 Etude de Phase I/IIa évaluant TG6002 (VV TK-RR-FCU1) administré par perfusion intra-veineuse (IV) en association avec la flucytosine (5-FC) par voie orale chez des patients atteints de tumeurs gastro-intestinales (GI) avancées

lead_sponsor: TRANSGENE S.A.


title: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors

acronym: MK-8628 Solid Tumor Trial

lead_sponsor: Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.


title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial)

lead_sponsor: Schering-Plough Research Institute


title: Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes

acronym: Safety and Efficacy of Moxidex Otic Solution in AOMT

lead_sponsor: Alcon Research Ltd.


title: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers

lead_sponsor: Hospital for Sick Children


title: Multi-center non-drug-interventional extension study to assess long-term safety and effects on growth in patients who received bosentan or placebo as adjunctive therapy to inhaled nitric oxide for persistent pulmonary hypertension of the newborn in FUTURE 4 (AC-052-391)

lead_sponsor: Actelion Pharmaceuticals Ltd.


title:
Vitamin D3 – Omega3 – Home Exercise – HeALTHy Ageing and Longevity
 Trial Randomized, double-blind, placebo-controlled, multi-centre clinical
 trial

 Vitamine D3 – Omega3 – Programme d’entraînement à la maison – longévité et vieillissement en bonne santé (DO-HEALTH)

acronym: DO – HEALTH

lead_sponsor: University Hospital of Zurich and City Hospital Waid


title: Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours.

acronym: ITCC 013 - TOTEM2

lead_sponsor: Institut Gustave Roussy


title: Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS)

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38825 for Org 36286 (corifollitropin alfa)

lead_sponsor: NV Organon


title: A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndrome

lead_sponsor: Pharmion Corporation


title: A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

lead_sponsor: Novartis Pharma Services AG


title: An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title:
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

 Étude de phase 1/2 évaluant la tolérance, la pharmacocinétique et l’activité antitumorale de l’inhibiteur oral de EGFR/HER2 TAK-788 (AP32788) dans les cancers du poumon non à petites cellules

lead_sponsor: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited


title:
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer
 (Master Protocol Revised version 02 dated 27-Jul-2016 + Sub-protocol 01 Revised version 01 dated 08-Apr-2016)

acronym: FRACTION-Lung

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

lead_sponsor: FORMA Therapeutics, Inc.


title: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment with Niraparib versus Ganetespib plus Carboplatin followed by Ganetespib and Niraparib versus Carboplatin in combination with standard chemotherapy followed by Niraparib maintenance treatment in platinum-sensitive ovarian cancer patients

acronym: EUDARIO: European Trial on enhanced DNA Repair Inhibition in Ovarian Cancer

lead_sponsor: Katholieke Universiteit Leuven


title:
Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study

 Etude clinique de la phase II multicentrique randomisée en double-aveugle testant l’efficacité de l’association d’Eltrombopag et de Lénalidomide contre placebo dans les SMD d’IPSS faible ou intermédiaire-1 avec del5q isolée

acronym:
QOL-ONE Rev2MDS

 QOL-ONE Rev2MDS

lead_sponsor: ASSOCIAZIONE QOL-ONE


title:
CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patients with severe Crigler-Najjar syndrome requiring phototherapy

 « CareCN : Etude de phase I/II,  en ouvert, avec escalade de dose, visant à évaluer la tolérance et l’efficacité d’un traitement par GNT0003 administré par voie intraveineuse chez des patients atteints d’un syndrome de Crigler-Najjar sévère nécessitant un traitement par photothérapie

acronym: CareCN

lead_sponsor: Genethon


title: Randomized, double-blind, placebo controlled, multi-centre, superiority phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in children from 3 months to less than 18 years of age experiencing severe chronic neuropathic or mixed pain.

acronym: Efficacy and safety study to compare gabapentin as add on to morphine in paediatric patients

lead_sponsor: PHARM – Pharmaceutical Research Management srl


title: Pulmonary vein isolation with versus without continued antiarrhythmic drug treatment in subjects with persistent atrial fibrillation: a prospective multi-centre randomized controlled clinical study (POWDER-AF2 study)

lead_sponsor: AZ Sint-Jan Brugge-Oostende AV


title: A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults

acronym: Ph 2a, GSK3640254, POC in HIV-1 infected Treatment-naive Adults

lead_sponsor: ViiV Healthcare UK Limited


title: A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribavirin

lead_sponsor: Schering Plough Research Institute, A Division of Schering Corporation


title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Naïve HIV-Infected Patients, Each in Combination With TRUVADA™

lead_sponsor: Laboratoires Merck Sharp & Dohme-Chibret


title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic Cell Tranplants (HCTs)

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.

acronym: HRA052015 in EAS

lead_sponsor: Laboratoire HRA Pharma


title: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection.

acronym: Altair

lead_sponsor: University of New South Wales


title: A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors

lead_sponsor: GlaxoSmithkline Research & Development Limited


title:
AN OPEN LABEL PHASE II STUDY  TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR-ABL+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
 EWALL-PH-01

acronym: EWALL

lead_sponsor: CH-Versailles


title: A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the effect on FEV1 of indacaterol 300 µg o.d. dosed in the evening in patients with moderate to severe chronic obstructive pulmonary disease (COPD) with salmeterol as active control

lead_sponsor: Novartis Pharma Services AG


title: An open-label, one arm, multi-centre Phase II trial evaluating the efficacy and safety of DTS-201 as a second-line chemotherapy in patients with hormone refractory prostate cancer

lead_sponsor: Diatos S.A.


title: Efficacy and safety assessment of intracameral T2380  (Fixed combination of lidocaïne, phenylephrine and tropicamide)  for anaesthesia and mydriasis in phacoemulsification cataract surgery

lead_sponsor: Laboratoires Théa


title: A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with essential hypertension


title: An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich's ataxia.

acronym: Not applicable

lead_sponsor: ApoPharma Incorporated


title: VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER

lead_sponsor: STEBA BIOTECH SA


title: International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression

lead_sponsor: ORVACS


title:
Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study

 Efficacité et sécurité d’une double dose d’icodextrine chez des patients âgés, incidents en dialyse péritonéale continue ambulatoire (DPCA), débutant une dialyse péritonéale incrémentale: l’étude DIDo

acronym: DIDo

lead_sponsor: Université catholique de Louvain


title: A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma


title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo- and Active Comparatorcontrolled
 Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

acronym: Delphinus

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization,Inc


title: Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia.

lead_sponsor: Pierre Fabre Medicament


title:
TIGER-1:  A Randomized, Open-label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic  Non-Small Cell Lung Cancer (NSCLC)

 TIGER-1 : Étude randomisée, ouverte, de phase 2/3 visant à évaluer le CO-1686 ou l’Erlotinib comme traitement de première ligne chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) muté EGFR à un stade avancé/métastatique

lead_sponsor: Clovis Oncology, Inc.


title:
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

 Etude de phase 2 visant à évaluer l'efficacité et la sécurité d'emploi de l'ACP-196 chez des patients atteints de LLC en rechute/réfractaire et présentant une intolérance au traitement par ibrutinib

lead_sponsor: Acerta Pharma, BV


title: A Long Term Follow-up Study of AMG0001 in Subjects with Critical Limb Ischemia

lead_sponsor: AnGes Inc.


title: A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer

acronym: CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versus an anti-pseudomonal-β lactam-based antibiotic in adult subjects with nosocomial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa.

lead_sponsor: Polyphor Ltd.


title: A randomized, open-label clinical trial to identify predictive factors for controlled ovarian stimulation using a fixed daily dose of 200 IU of recombinant FSH in a GnRH antagonist regimen with or without oral contraceptive scheduling

lead_sponsor: NV Organon


title: A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase.


title: Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa)


title: An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: "VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE"

lead_sponsor: STEBA BIOTECH NV


title: A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension.

lead_sponsor: Novartis Pharma Services AG


title: A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects.

lead_sponsor: GlaxoSmithKline Research and Development Ltd


title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study

acronym: The BRISK TA Study

lead_sponsor: Bristol Myers Squibb International Corporation


title: Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation

lead_sponsor: EBMT (European group for Blood and Marrow Transplantation)


title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: FEIBA NF: A prospective, open-label, randomized, parallel study to evaluate efficacy and safety of prophylactic versus on-demand treatment in subjects with hemophilia A or B and a high titer inhibitor

acronym: FEIBA NF Prophylaxis Study

lead_sponsor: Baxter Innovations GmbH


title: A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation.

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 22.7, 45.5, and 90.9 µg b.i.d. administered via Respimat® inhaler and fluticasone propionate HFA MDI 88 µg b.i.d. in patients with asthma inadequately controlled on SABA therapy.

lead_sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG,


title: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

lead_sponsor: Astellas Pharma Global Development, Inc.


title:
Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis

 Étude préliminaire phase II auprès de patients après traitement de tumeurs cérébrales de haut grade pour déterminer la performance technique du Tc-99m tétrofosmine pour différencier la tumeur récidivante de la nécrose de rayonnement

lead_sponsor: pro-ACTINA S.A.


title:
A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

 Étude randomisée de phase 3, en double aveugle, contrôlée versus placebo, évaluant le traitement par pazopanib avec ou sans abexinostat chez des patients présentant un cancer du rein localement avancé ou métastatique

lead_sponsor: Xynomic Pharmaceuticals, Inc.


title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

lead_sponsor: AstraZeneca AB


title: A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1)

lead_sponsor: INNOVIVE Pharmaceuticals


title: A multicenter, randomized, double-blind, placebo-controlled parallel-group phase IIb study of the safety and efficacy of istaroxime over 24 hours at three doses in acute decompensated heart failure patients. The IGNITE Trial.

acronym: IGNITE Trial

lead_sponsor: Debiopharm S.A.


title: A Phase IIb pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance

acronym: VIKING


title: The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by Acadesine in Subjects Undergoing CABG)

acronym: RED-CABG Trial

lead_sponsor: Schering-Plough Research Institute, a Division of Schering Corporation


title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus

lead_sponsor: SmithKline Beecham Corporation (doing business as GlaxoSmithKline)


title: Phase I/II/III Pharmacokinetic and Outcome Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia B

lead_sponsor: Inspiration Biopharmaceuticals


title: A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women

lead_sponsor: Merck & Co., Inc.


title: An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 mg adult tablet (part A) followed by an open, non-randomised multiple-doses study with adjusted doses of 6MP oral liquid formulation (part B)  in children with acute lymphoblastic leukaemia.

lead_sponsor: Only For Children Pharmaceuticals


title: A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virologically failing first-line NNRTI/2N(t)RTI therapy: the SECOND-LINE study

acronym: SECOND-LINE

lead_sponsor: National Centre in HIV Epidemiology and Clinical Research


title: Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer.


title:
A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients.

 Une étude de phase 2 randomisée comparant différentes approches posologiques dans le traitement par induction (premier cycle) du régorafénib chez des patients adultes atteints d'un cancer colorectal métastatique (CCRm).

acronym:
RE-ARRANGE

 RE-ARRANGE

lead_sponsor: Grupo de Tratamiento de los Tumores Digestivos (TTD)


title:
A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure

 Etude prospective, en ouvert, contrôlée versus traitement actif, pour évaluer la pharmacocinétique, la pharmacodynamie, la sécurité d’emploi et l’efficacité du rivaroxaban dans la thromboprophylaxie chez des patients âgés de 2 à 8 ans, ayant subi une procédure de Fontan

acronym: UNIVERSE

lead_sponsor: Janssen-Cilag International N.V


title: Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with sepsis-associated acute kidney injury (SA-AKI)

acronym: REAKT

lead_sponsor: Atox Bio


title: An open label, 3-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib in combination with either Chemotherapy or Blinatumomab with Imatinib plus Chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL)

lead_sponsor: Cardiff University